Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics EndoPredict Test

Myriad Genetics has launched the EndoPredict test, a second-generation test for assessing the 10-year risk of disease recurrence in patients with ER+ HER2- early-stage breast cancer. The test includes proliferation-related genes and hormone receptor-related genes to provide clinicians with an accurate assessment of early and late risk recurrence, the company said. It uses this information to definitively classify patients as low or high risk, which helps clinicians make therapy decisions going forward.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

Higher polygenic risk scores for attention-deficit/hyperactivity disorder were also linked to cognitive decline and Alzheimer's disease risk, according to a new study in Molecular Psychiatry.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.